2. Search Result
Search Result
Results for "

P. berghei

" in MedChemExpress (MCE) Product Catalog:

16

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15975
    GNF179

    		Parasite Infection
    GNF179 is an optimized 8,8-dimethyl imidazolopiperazine analog that exhibits antimalarial potency (IC50 of 4.8 nM against the multidrug resistant strain W2). GNF179 is orally active .
    GNF179
  • HY-155689
    Antimalarial agent 30

    		Parasite Infection
    Antimalarial agent 30 (compound 11) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC50 of 5.2 μM .
    Antimalarial agent 30
  • HY-155688
    Antimalarial agent 29

    		Parasite Infection
    Antimalarial agent 29 (compound 16) is an antimalarial agent that inhibits P. berghei liver stage parasite load with an EC50 of 5.2 μM .
    Antimalarial agent 29
  • HY-118537
    ICI 56780

    		Parasite Infection
    ICI 56780 is an antimalarial agent, that exhibits etiological prevention and blood schizonticidal activity in rodent malaria models. ICI 56780 develops parasite resistance in P. berghei infected mice .
    ICI 56780
  • HY-152614
    Antimalarial agent 19

    		Parasite Infection
    Antimalarial agent 19 (compound 6e) is an antimalarial active agent. Antimalarial agent 19 has antimalarial activity for the blood stage of P. falciparum K1 and P. berghei with EC50 values of 0.3 µM, 15.3 µM, respectively. Antimalarial agent 19 has good aqueous solubility, intestinal permeability and microsomal stability compared to gamhepathiopine .
    Antimalarial agent 19
  • HY-116736
    BRD7539

    		Dihydroorotate Dehydrogenase Parasite Infection
    BRD7539 is a PfDHODH inhibitor (IC50 = 0.033 μM). BRD7539 has potent activity against both multidrug-resistant asexual blood-stage (P. falciparum, Dd2 strain, EC50 = 0.010 μM) and liver-stage (P. berghei, EC50 = 0.015 μM) parasites .
    BRD7539
  • HY-124112
    PAM 1392

    		Parasite Infection
    PAM 1392 is active orally against Plasmodium berghei in mice, P. cynofologi and P. knowlesi in monkeys and Trypanosoma cruzi in tissue cultures of mice, and hemolytic streptococci in vitro. PAM 1392 has antimalarial and antitrypanosomal activities, which is proming for rasearch of drug-resistant malaria .
    PAM 1392
  • HY-120462
    Genz-669178

    		Dihydroorotate Dehydrogenase Parasite Infection
    Genz-669178 is an inhibitor for dihydroorotate dehydrogenase (DHODH) with IC50 of 0.015-0.05 μM in Plasmodium spp.. Genz-669178 inhibits P. berghei, P. falciparum strains 3D7 and Dd2 with IC50 of 0.068, 0.008 and 0.01 μM, respectively. Genz-669178 exhibits anti-malarial efficacy in P. berghei-infected mice with ED50 of 13-21 mg/kg/day. Genz-669178 exhibits good pharmacokinetic characteristics in mice .
    Genz-669178
  • HY-120924
    BRD9185

    		Dihydroorotate Dehydrogenase DNA/RNA Synthesis Parasite Infection
    BRD9185 is a Dihydroorotate dehydrogenase (DHODH) inhibitor, with an EC50 of 16 nM against multidrug-resistant blood-stage parasites in vitro and is curative after just three doses in a P. berghei mouse model .
    BRD9185
  • HY-155536
    Antimalarial agent 28

    		Parasite Infection
    Antimalarial agent 28 (Compound 2i) is an antiplasmodial agent. Antimalarial agent 28 inhibits P. berghei, with IC50s of 0.561 μM, 0.14 μM, 4.34 μM for Liver stage, early gametocytes and ring stages of P. falciparum .
    Antimalarial agent 28
  • HY-119046
    SNX-0723

    		HSP Parasite Infection
    SNX-0723 is a potent Hsp90 Inhibitor with anti-Plasmodium activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with Kis of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC50 of 3.3 μM .
    SNX-0723
  • HY-128204
    AN3661
    1 Publications Verification

    		 Parasite Infection
    AN3661, a potent antimalarial lead compound, targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue subunit 3 (PfCPSF3). AN3661 inhibits Plasmodium falciparum laboratory-adapted strains (mean IC50=32 nM), Ugandan field isolates (mean ex vivo IC50=64 nM), and murine P. berghei and P. falciparum infections .
    AN3661
  • HY-111817A
    (Rac)-ACT-451840

    		Parasite Infection
    (Rac)-ACT-451840 is an isomer of ACT-451840 that exhibits significant antimalarial effects. (Rac)-ACT-451840 exhibits significant antimalarial activity against P. berghei-infected mice at a dose of 20 mg/kg (ED90=13 mg/kg), and has an inhibitory effect at a dose of 300 mg/kg. The ED90 of (Rac)-ACT-451840 in the P. falciparum humanized immunodeficient mouse model is 3.7 mg/kg. (Rac)-ACT-451840 is similar to artemisinin, with a rapid onset of action but requires repeated high doses.
    (Rac)-ACT-451840
  • HY-147849
    JMI-105

    		Parasite Infection
    JMI-105 is a potent PfFP-2 (Plasmodium falciparum falcipain-2 protease) inhibitor. JMI-105 inhibits the growth of CQ S (3D7; IC50=8.8 µM) and CQ R (RKL-9; IC50=14.3 µM) strains of P. falciparum. JMI-105 significantly decreases parasitemia and prolonged host survival in a murine model with P. berghei ANKA infection. JMI-105 has the potential to be used as an anti-malarial agent .
    JMI-105
  • HY-155846
    Antileishmanial agent-22

    		Parasite Bacterial Infection
    Antileishmanial agent-22 (compound 15b) is a parasite inhibitor and an antibacterial agent, with antileishmanial, antimalarial, and anti-tubercular activities. Antileishmanial agent-22 inhibits leishmanial (IC50=0.408 μM) based on antifolate mechanism. And, Antileishmanial agent-22 inhibits Folic acid and Folinic acid at 100 μM with inhibitory rates of 88% and 94%, respectively. Antileishmanial agent-22 inhibits P. berghei in vivo and in vitro, with 96.67% suppression under 48.4 μM/kg/day and 0.038 μM (IC50), respectively. Moreover, Antileishmanial agent-22 inhibits M. tuberculosis with MIC of 28.44 μM .
    Antileishmanial agent-22
  • HY-W071746
    Linolelaidic acid

    Linoelaidic acid

    		 Endogenous Metabolite Parasite Apoptosis Infection Inflammation/Immunology
    Linolelaidic acid (Linoelaidic acid) is an omega-6 trans fatty acid (TFA) that is an essential nutrient with oral activity. Linolelaidic acid can be added to enteral nutrition (oral), parenteral nutrition (intravenous), and infant formula. Linolelaidic acid has anti-inflammatory and anti-parasitic ((Parasite)) activities, and can induce Apoptosis. Linolelaidic acid is useful for research in infections .
    Linolelaidic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: